LAG-3 as a Third Checkpoint: Mechanistic Differentiation from PD-1
LAG-3 (Lymphocyte Activation Gene-3) is a third immune checkpoint target that is mechanistically distinct from PD-1/PD-L1 and CTLA-4 — the two pathways that dominated the first decade of checkpoint immunotherapy. Relatlimab is an anti-LAG-3 antibody that blocks this receptor, while nivolumab blocks PD-1; together, they constitute a dual-checkpoint blockade strategy with a different immunosuppressive target profile than any PD-1 monotherapy, including pembrolizumab.
The significance of LAG-3 as a target lies in its distinct mechanism of T-cell suppression. While PD-1 primarily attenuates T-cell activation signals at the effector phase, LAG-3 is expressed on exhausted T cells and regulatory T cells, contributing to a separate immunosuppressive axis. Co-blocking both pathways simultaneously is the scientific rationale for combining relatlimab with nivolumab rather than using either agent alone.
Relatlimab is an anti-LAG-3 antibody that blocks the LAG-3 immune checkpoint receptor, while nivolumab blocks PD-1. Together, they constitute a dual-checkpoint blockade strategy that is mechanistically distinct from PD-1 monotherapy agents such as pembrolizumab in the adjuvant melanoma setting.
This mechanistic differentiation is central to understanding the competitive positioning of the relatlimab plus nivolumab combination against pembrolizumab, which targets only the PD-1 pathway. The adjuvant melanoma setting — where patients have had their tumours surgically resected but face a high risk of recurrence — is precisely the context in which the depth and durability of immune activation may determine long-term outcomes. According to the National Cancer Institute, adjuvant immunotherapy aims to eliminate residual micrometastatic disease after surgery, making the choice of checkpoint combination particularly consequential.
The Adjuvant Melanoma Treatment Landscape After PD-1 Approval
The adjuvant treatment of resected high-risk melanoma has undergone significant transformation with the approval of immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 pathways. Before the introduction of checkpoint inhibitors, adjuvant options were limited and associated with modest efficacy; the approval of PD-1 agents established a new standard of care that substantially reduced recurrence rates in high-risk resected disease.
Adjuvant immunotherapy refers to systemic treatment administered after surgical resection of a tumour, with the goal of eliminating residual micrometastatic disease and reducing the risk of disease recurrence. In melanoma, adjuvant checkpoint inhibitors target patients with resected stage III or high-risk stage II disease.
Pembrolizumab, which blocks PD-1, became a cornerstone of adjuvant melanoma treatment following regulatory approvals supported by recurrence-free survival data. As a PD-1 monotherapy, pembrolizumab activates T cells by releasing the PD-1-mediated brake on immune responses. The clinical question now facing oncologists and payers is whether the addition of LAG-3 blockade — as provided by relatlimab — offers meaningful incremental benefit over PD-1 monotherapy alone, particularly in terms of recurrence-free survival and overall survival in the adjuvant context.
The adjuvant treatment of resected high-risk melanoma has undergone significant transformation with the approval of immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 pathways. The emergence of LAG-3 as a third checkpoint target — co-blocked by relatlimab in combination with nivolumab — introduces a mechanistically distinct dual-checkpoint strategy that competes directly with established PD-1 monotherapy agents such as pembrolizumab in the adjuvant setting.
Regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency evaluate adjuvant therapies on the basis of recurrence-free survival as a primary endpoint, with overall survival as a key secondary endpoint. The competitive landscape in adjuvant melanoma is therefore defined not only by mechanistic differentiation but by the clinical trial data underpinning regulatory submissions — data that, for the relatlimab plus nivolumab combination in the adjuvant setting specifically, remains an active area of investigation and publication.
Explore the full patent and clinical intelligence landscape for LAG-3 checkpoint inhibitors in melanoma.
Analyse Patents with PatSnap Eureka →Dual-Checkpoint Blockade: How Relatlimab + Nivolumab Competes
The relatlimab plus nivolumab combination competes with pembrolizumab in adjuvant melanoma by offering simultaneous blockade of two distinct immunosuppressive checkpoints — LAG-3 and PD-1 — rather than the single PD-1 pathway targeted by pembrolizumab. This dual-checkpoint strategy is the mechanistic basis for the competitive differentiation of the combination.
“The emergence of LAG-3 as a third checkpoint target — co-blocked by relatlimab in combination with nivolumab — introduces a mechanistically distinct dual-checkpoint strategy that now competes directly with established PD-1 monotherapy agents such as pembrolizumab in the adjuvant setting.”
LAG-3 is expressed on exhausted T cells and regulatory T cells, contributing to immune suppression through a pathway that operates in parallel to — and independently of — the PD-1 axis. By blocking both pathways simultaneously, the relatlimab plus nivolumab combination theoretically addresses a broader immunosuppressive environment within the tumour microenvironment and in the systemic immune compartment relevant to micrometastatic disease in the adjuvant context.
Relatlimab plus nivolumab is the only approved therapeutic combination to co-block both LAG-3 and PD-1 simultaneously. This dual-checkpoint mechanism is mechanistically distinct from pembrolizumab, which blocks PD-1 alone, and from ipilimumab, which blocks CTLA-4 alone.
The competitive question for oncologists, payers, and IP strategists is whether this mechanistic distinction translates into superior or differentiated clinical outcomes — specifically recurrence-free survival and overall survival — in the adjuvant melanoma population. According to the American Society of Clinical Oncology, head-to-head comparative data between the two regimens in the adjuvant setting had not been established as of the time of this analysis, making indirect comparisons across separate trial populations the current standard for competitive assessment.
IP Assignee Landscape: Bristol-Myers Squibb vs. Merck
The intellectual property landscape for adjuvant melanoma checkpoint immunotherapy is anchored by two primary assignees: Bristol-Myers Squibb (BMS), the developer of the relatlimab plus nivolumab combination, and Merck, the developer of pembrolizumab. Understanding the patent family structures of each is essential for competitive intelligence, freedom-to-operate analysis, and forecasting exclusivity timelines.
Bristol-Myers Squibb is the primary assignee for relatlimab and nivolumab combination patents in the LAG-3 checkpoint inhibitor space, while Merck holds the key patent families for pembrolizumab. Both companies are central to the IP landscape of adjuvant melanoma immune checkpoint therapy.
For analysts seeking to map the LAG-3 patent landscape, the recommended approach involves assignee-targeted queries for Bristol-Myers Squibb with LAG-3 patent family filters, combined with mechanism-focused searches using terms such as “LAG-3 inhibitor nivolumab relatlimab checkpoint.” On the pembrolizumab side, Merck’s patent portfolio covers both the antibody composition and its clinical applications, with adjuvant melanoma indications forming a distinct sub-category of the broader PD-1 blockade IP estate.
Patent strategy in the checkpoint inhibitor space is also shaped by the World Intellectual Property Organization‘s PCT framework, which governs international filing and national phase entry timelines for both BMS and Merck patent families. Freedom-to-operate assessments in this space must account for composition-of-matter patents, method-of-treatment claims, and combination therapy claims — each of which may carry different expiry dates and jurisdictional coverage.
Map the full LAG-3 and PD-1 patent family landscape with PatSnap Eureka’s AI-powered IP intelligence.
Explore Patent Families in PatSnap Eureka →Evidence Gaps and What Analysts Should Know
A structured search protocol spanning three independent search dimensions — core LAG-3 checkpoint mechanisms, adjuvant melanoma clinical applications, and combination immunotherapy IP assignee landscape — returned no retrievable records for this specific topic combination at the time of query execution. This outcome reflects a genuine evidence gap in the retrievable literature for the precise intersection of relatlimab plus nivolumab versus pembrolizumab in the adjuvant melanoma setting, rather than an absence of scientific or clinical activity in this area.
The structured search protocol executed for this analysis returned zero retrievable records for the specific combination of relatlimab plus nivolumab versus pembrolizumab in the adjuvant melanoma setting across three independent search dimensions. The analysis presented here is derived from the contextual framing provided in the source brief and does not include cited primary survival endpoint data. Analysts are advised to retry searches using the recommended strategies below and to consult primary trial registries for the most current recurrence-free survival and overall survival data.
For analysts or system operators seeking to obtain primary survival endpoint data, the following search refinement strategies are recommended based on the source brief:
- Mechanism dimension: Search terms such as “LAG-3 inhibitor nivolumab relatlimab checkpoint” combined with sources covering all databases and both semantic and keyword strategies.
- Clinical dimension: Terms including “adjuvant melanoma PD-1 survival recurrence-free pembrolizumab” with a date filter for 2020–2025, targeting clinical trial registries and peer-reviewed oncology journals.
- IP/assignee dimension: Assignee-targeted queries for Bristol-Myers Squibb (relatlimab/nivolumab) and Merck (pembrolizumab) with LAG-3 patent family filters applied across major patent databases.
Primary clinical trial data for the relatlimab plus nivolumab combination in melanoma — including the RELATIVITY-047 trial — and for pembrolizumab in adjuvant melanoma — including the KEYNOTE-716 and KEYNOTE-054 trials — are accessible through public registries such as ClinicalTrials.gov. Analysts conducting competitive survival assessments should access these primary sources directly to obtain the most current and complete recurrence-free survival and overall survival data.